Whole body pet for the evaluation of bony metastases in patients with breast cancer: Comparison with 99tcm-mdp bone scintigraphy

Nuclear Medicine Communications

Volumn 22, Issue 8, 2001, Pages 875-879

  Ohta, M ^a   Tokuda, Y ^a   Suzuki, Y ^a   Kubota, M ^a   Makuuchi, H ^a   Tajima, T ^a   Nasu, S ^a   Yasuda, S ^a   Shohtsu, A ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bony metastases; Breast cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY;

ADULT; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034917332     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200108000-00005     Document Type: Review

References (20)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6.
2. Guzzo CE, Pachas WN, Pinals RS, Krant MJ. Urinary hydroxyproline excretion in patients with cancer. Cancer 1969; 24: 382-7.
3. Gielen F, Dequeker J, Drochmans A, Wildiers J, Merlevede M. Relevance of hydroxyproline excretion to bone metastasis in breast cancer. Br J Cancer 1976; 34: 279-85.
4. Fogelman I. Bone scanning. In: Maisey MN, Britton KE, Gilday DL, eds. Clinical nuclear medicine. London: Chapman and Hall, 1991: 131.
5. Colman LK, Porter BA, Redmond III J et al. Early diagnosis of spinal metastases by CT and MR studies. J Comput Assist Tomogr 1988; 12: 423-6.
6. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23: 618-23.
7. Bombardieri E, Crippa F, Maffioli L et al. Nuclear medicine approaches for detection of axillary lymph node metastases. Q J Nucl Med 1998; 42: 59-65.
8. Holle L, Trampert L, Lung-Kurt S et al. Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nucl Med 1996; 37(4): 615-22.
9. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13: 1097-8.
10. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-70.
11. Tse NY, Hoh CK, Hawkins RA et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216(1): 27-34.
12. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-50.
13. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 1994; 35: 872-5.
14. Pietrzyk U, Scheidhauer K, Scharl A, Schuster A, Schicha H. Presurgical visualization of primary breast carcinoma with PET emission and transmission imaging. J Nucl Med 1995; 36: 1882-4.
15. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-11.
16. Bassa P, Kim EE, Inoue T et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37: 931-8.
17. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9.
18. Aydiner A, Topuz E, Disci R et al. Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol 1994; 33: 181-6.
19. Theriault RL, Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs 1992; 3: 455-62.
20. Diel IJ, Solomayer E, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63.